scholarly journals Genetic testing and diagnosis of inherited retinal diseases

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
Byron L. Lam ◽  
Bart P. Leroy ◽  
Graeme Black ◽  
Tuyen Ong ◽  
Dan Yoon ◽  
...  

AbstractInherited retinal diseases (IRDs) are a diverse group of degenerative diseases of the retina that can lead to significant reduction in vision and blindness. Because of the considerable phenotypic overlap among IRDs, genetic testing is a critical step in obtaining a definitive diagnosis for affected individuals and enabling access to emerging gene therapy–based treatments and ongoing clinical studies. While advances in molecular diagnostic technologies have significantly improved the understanding of IRDs and identification of disease-causing variants, training in genetic diagnostics among ophthalmologists is limited. In this review, we will provide ophthalmologists with an overview of genetic testing for IRDs, including the types of available testing, variant interpretation, and genetic counseling. Additionally, we will discuss the clinical applications of genetic testing in the molecular diagnosis of IRDs through case studies.

2001 ◽  
Vol 47 (6) ◽  
pp. 990-1000 ◽  
Author(s):  
Carole A Foy ◽  
Helen C Parkes

Abstract Background: Advances in molecular diagnostic technologies have enabled genetic testing in single closed-tube reactions. The purpose of this review is to highlight some of the platforms and technologies currently available for the homogeneous detection of targets and the application of the technologies in the clinical setting. Validation issues surrounding the technologies, which may need to be addressed before they can become widely accepted, will also be discussed. Approach: This review discusses the principles of several of the major technologies available for performing homogeneous genetic analyses. Publications arising from the application of the technologies in a wide range of clinical areas are used to highlight and compare the potential advantages and shortcomings of the various technologies. Content: This review is descriptive and focuses on three areas: the technologies available for performing homogeneous analysis, the clinical applications where the technologies are being used, and validation issues surrounding the acceptance of the technologies in the general clinical setting. Summary: This review intends to give the reader a greater understanding of the various technologies available for performing homogeneous genetic testing in the clinical laboratory. Through insight into the principles and performance characteristics underlying these technologies, the end user can evaluate their value and limitations in the clinical diagnostic setting.


2015 ◽  
Vol 38 (3) ◽  
pp. 332-337 ◽  
Author(s):  
Rosane Paixão Schlatter ◽  
Ursula Matte ◽  
Carisi Anne Polanczyk ◽  
Patrícia Koehler-Santos ◽  
Patricia Ashton-Prolla

Author(s):  
Ahmad Al-Moujahed ◽  
Aarushi Kumar ◽  
Teja Chemudupati ◽  
Stephen H. Tsang ◽  
Vinit B. Mahajan

AbstractInherited retinal diseases (IRDs) are visually debilitating conditions that affect families worldwide. They require extensive clinical testing, examination, and patient and family counseling, which are frequently accomplished over single-day extended clinic visits. However, the COVID-19 pandemic has limited the number of patients and staff allowed in clinics, leading to interruptions in care. We therefore developed telehealth management protocols for complete or hybrid virtual visits. The three main components of our telegenetics approach included reviewing the diagnostic tests results remotely, in-person or virtual video visits with a retina specialist, and virtual genetic testing using saliva kits. During the first 5 months of the program, telegenetic care was provided for 80 patients, including 3 international patients, and a spectrum of retinal dystrophies were diagnosed and managed. In conclusion, telegenetic virtual visits ensure continuity of care while reducing patient and provider exposure to SARS-CoV-2 and may continue and expand into other medical genetic conditions long after the pandemic.


2010 ◽  
Vol 51 (11) ◽  
pp. 5403 ◽  
Author(s):  
Henry F. Edelhauser ◽  
Cheryl L. Rowe-Rendleman ◽  
Michael R. Robinson ◽  
Daniel G. Dawson ◽  
Gerald J. Chader ◽  
...  

2003 ◽  
Vol 127 (12) ◽  
pp. 1565-1572
Author(s):  
Susan H. Bernacki ◽  
Daniel H. Farkas ◽  
Wenmei Shi ◽  
Vivian Chan ◽  
Yenbou Liu ◽  
...  

Abstract Context.—Bioelectronic sensors, which combine microchip and biological components, are an emerging technology in clinical diagnostic testing. An electronic detection platform using DNA biochip technology (eSensor) is under development for molecular diagnostic applications. Owing to the novelty of these devices, demonstrations of their successful use in practical diagnostic applications are limited. Objective.—To assess the performance of the eSensor bioelectronic method in the validation of 6 Epstein-Barr virus–transformed blood lymphocyte cell lines with clinically important mutations for use as sources of genetic material for positive controls in clinical molecular genetic testing. Two cell lines carry mutations in the CFTR gene (cystic fibrosis), and 4 carry mutations in the HFE gene (hereditary hemochromatosis). Design.—Samples from each cell line were sent for genotype determination to 6 different molecular genetic testing facilities, including the laboratory developing the DNA biochips. In addition to the bioelectronic method, at least 3 different molecular diagnostic methods were used in the analysis of each cell line. Detailed data were collected from the DNA biochip output, and the genetic results were compared with those obtained using the more established methods. Results.—We report the successful use of 2 applications of the bioelectronic platform, one for detection of CFTR mutations and the other for detection of HFE mutations. In all cases, the results obtained with the DNA biochip were in concordance with those reported for the other methods. Electronic signal output from the DNA biochips clearly differentiated between mutated and wild-type alleles. This is the first report of the use of the cystic fibrosis detection platform. Conclusions.—Bioelectronic sensors for the detection of disease-causing mutations performed well when used in a “real-life” situation, in this case, a validation study of positive control blood lymphocyte cell lines with mutations of public health importance. This study illustrates the practical potential of emerging bioelectronic DNA detection technologies for use in current molecular diagnostic applications.


Author(s):  
Courtney Berrios ◽  
Emily A. Hurley ◽  
Laurel Willig ◽  
Isabelle Thiffault ◽  
Carol Saunders ◽  
...  

2018 ◽  
Vol 123 (2) ◽  
pp. S101-S102
Author(s):  
Laura Murillo ◽  
Rachel Harte ◽  
Stacey Wong ◽  
Yuan-Yuan Ho ◽  
Daniel Beltran ◽  
...  

Genes ◽  
2020 ◽  
Vol 11 (11) ◽  
pp. 1274
Author(s):  
Jamie M. Ellingford ◽  
Robert B. Hufnagel ◽  
Gavin Arno

Inherited retinal diseases (IRDs) are a diverse and variable group of rare human disorders [...]


Sign in / Sign up

Export Citation Format

Share Document